Results 51 to 60 of about 27,849,568 (325)
Gastroenterology Research and Practice, 2021 Changes in intestinal microbiota have been linked to the development of diarrhea predominant irritable bowel syndrome (IBS-D). In order to better elucidate the relationship between intestinal microbiota changes and IBS-D, we compared fecal microbiota of ...
Fang Yang +6 more
doaj +1 more source
Clinical and Translational Gastroenterology, 2021 INTRODUCTION: Despite heterogeneity, an increased prevalence of psychological comorbidity and an altered pronociceptive gut microenvironment have repeatedly emerged as causative pathophysiology in patients with irritable bowel syndrome (IBS). Our aim was
V. Cibert-Goton +6 more
semanticscholar +1 more source
Evaluation of prakṛti and quality-of-life in patients with irritable bowel syndrome
Ancient Science of Life, 2015 Objective: To evaluate the prakṛti of irritable bowel syndrome (IBS) patients and its association with IBS subtypes and quality-of-life (QOL). Methodology: IBS patients with the consistent subtype in the last 6 months were recruited.
Sudatta G Shirolkar +2 more
doaj +1 more source
Frontiers in Pharmacology, 2018 Tong-Xie-Yao-Fang (TXYF) has been widely used for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) in traditional Chinese medicine. However, its mechanism of action in the treatment of IBS-D remains to be fully understood.
Junchen Li +9 more
doaj +1 more source
Gastroenterology Research and Practice, 2016 Background and Aims. Although the differential expression of microRNA (miRNA) genes has been identified in many diseases, little information exists concerning the miRNA expression profile in type 2 diabetes mellitus (T2DM) with diarrhea-predominant ...
Wenhua Tao +5 more
doaj +1 more source
Golden bifid might improve diarrhea-predominant irritable bowel syndrome via microbiota modulation
Journal of Health, Population and Nutrition, 2022 Objective Gut microbiota might play a crucial role in the pathogenesis of irritable bowel syndrome (IBS), and probiotics supplement may be an effective treatment option.
Mei Luo +3 more
doaj +1 more source
Oral and fecal microbiota in patients with diarrheal irritable bowel syndrome
Heliyon, 2023 Background: This study aimed at investigating the characteristics and correlation between oral (tongue coating) and fecal microbiota in patients with diarrheal irritable bowel syndrome (IBS-D).
Binbin Tang +5 more
doaj +1 more source
Two new choices for patients with IBS-D [PDF]
Pharmacy Today, 2015 Eluxadoline (Viberzi—Patheon), a novel medication, and rifaximin (Xifaxan—Salix), a previously approved agent, have received FDA approval for the treatment of adult patients with irritable bowel syndrome with diarrhea (IBS-D). The condition affects an estimated 15 million patients in the United States, with women twice as likely as men to have IBS-D.
openaire +1 more source
Gut microbiome signatures reflect different subtypes of irritable bowel syndrome
Gut Microbes, 2023 Irritable bowel syndrome (IBS) is a heterogeneous condition with multifactorial pathogenesis. We studied deeply phenotyped individuals with microbiota sequencing enrolled in the American Gut Project.
Qi Su +6 more
doaj +1 more source
Contemporary management of pain in cirrhosis: Toward precision therapy for pain
Hepatology, EarlyView., 2022 Abstract Chronic pain is highly prevalent in patients with cirrhosis and is associated with poor health‐related quality of life and poor functional status. However, there is limited guidance on appropriate pain management in this population, and pharmacologic treatment can be harmful, leading to adverse outcomes, such as gastrointestinal bleeding ...
Alexis Holman +4 more
wiley +1 more source